Author

T. Sakura

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:plant (other)· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

K. Kita· 3 shared D. K. Inaoka· 2 shared D. Ken Inaoka· 1 shared E. S. H. Hayakawa· 1 shared E. Yoshida· 1 shared F. Tokumasu· 1 shared H. Shindou· 1 shared J. Fukumoto· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

K. Kita

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Accelerating antimalarial drug discovery with a new high-throughput screen for fast-killing compounds

T. Sakura, R. Ishii, E. Yoshida, K. Kita, T. Kato, D. K. Inaoka

This paper introduces a high-throughput screening method to identify fast-killing antimalarial compounds by measuring parasite reduction ratio using Plasmodium falciparum lactate dehydrogenase and fluorescent probes.

bioRxiv · Apr 21, 2024Microbiology

Pivotal roles of Plasmodium falciparum lysophospholipid acyltransferase 1 in cell cycle progression and cytostome internalization

J. Fukumoto, M. Yoshida, S. M. Tokuoka, E. S. H. Hayakawa, S. Miyazaki, T. Sakura, D. Ken Inaoka, K. Kita, J. Usukura, H. Shindou, F. Tokumasu

This study identifies PfLPLAT1 as essential for Plasmodium falciparum cell cycle progression and cytostome function, with its deficiency causing developmental arrest and morphological changes.

bioRxiv · Jan 13, 2024 · PreprintMicrobiology

5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro

Y. Sakurai, M. M. N. Tun, Y. Kurosaki, T. Sakura, D. K. Inaoka, K. Fujine, K. Kita, K. Morita, J. Yasuda

This study shows that 5-ALA inhibits SARS-CoV-2 infection in vitro in both human and non-human cells with low cytotoxicity, suggesting it as a potential oral antiviral drug for COVID-19.

bioRxiv · Oct 28, 2020Microbiology